Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T20:33:21.980Z.
Calculation as of: 2026-10-06T20:33:21.980Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 85c5299a8cd03ba6ccd909ec362e0e14be7ffdf82dbb7ad991ebf1e2cdc97105
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Universe Pharmaceuticals Inc.
Market Cap
$2.66M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| Universe Pharmaceuticals Inc. (UPC) | $2.66M | N/A |
| iSpecimen Inc. (ISPC)vs › | $2.69M | N/A |
| Nuwellis, Inc. (NUWE)vs › | $2.56M | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.54M | N/A |
| IceCure Medical Ltd (ICCM)vs › | $2.86M | N/A |
| Jaguar Health, Inc. (JAGX)vs › | $2.44M | N/A |
| Revelation Biosciences, Inc. (REVB)vs › | $2.94M | N/A |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.38M | N/A |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.38M | N/A |
| Onconetix, Inc. (ONCO)vs › | $2.37M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
